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a b s t r a c t
Introduction: Glycerol preserved acellular dermis (Glyaderm1) consists of collagen and elastin
fibers and is the first non-profit dermal substitute derived from glycerol-preserved, human
allogeneic skin. It is indicated for bi-layered skin reconstruction of full thickness wounds.
Methods: A protocol for clinical application and optimal interval before autografting with
split thickness skin graft (STSG) was developed in a pilot study.
A phase III randomized, controlled, paired, intra-individual study compared full thick-
ness defects engrafted with Glyaderm1 and STSG versus STSG alone.
Outcome measures included percentage of Glyaderm1 take, STSG take, and scar quality
assessment.
Results: Pilot study (27 patients): Mean take rates equaled 91.55% for Glyaderm1 and 96.67%
for STSG. The optimal autografting interval was 6 days (1 day).
Randomized trial (28 patients): Mean Glyaderm1 take rate was 88.17%. STSG take rates were
comparable for both research groups ( p = 0.588). One year after wound closure, Glya-
derm1 + STSG was significantly more elastic ( p = 0.003) than STSG alone. Blinded observers
scored Glyaderm1 treated wounds better in terms of scar quality.
Discussion: The efficacy of Glyaderm1 as a suitable dermal substitute for full thickness
wounds is attested. Currently a procedure for simultaneous application of Glyaderm1 and
STSG is adopted, allowing for further widespread use of Glyaderm1.
# 2014 Elsevier Ltd and ISBI. All rights reserved.
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier.com/locate/burns1. Introduction
Dermal substitution has become an integral part of surgical
burn care and many commercial dermal equivalents have
emerged on the market since the introduction of Integra1
dermal substitute (Integra LifeSciences Corporation) some two
decades ago [1–3].* Corresponding author at: Department of Plastic Surgery, Burn Center, G
fax: +32 93 32 38 99.
E-mail addresses: Stan.Monstrey@UGent.be, vp15vnj@hotmail.com
http://dx.doi.org/10.1016/j.burns.2014.05.013
0305-4179/# 2014 Elsevier Ltd and ISBI. All rights reserved.We extensively reported on the various cellular, acellular,
temporary and permanent skin replacements available for
burns and full thickness defects in a previous publication [4].
Glycerol preserved acellular dermis (Glyaderm1 – Euro Skin
Bank, Beverwijk, The Netherlands) is the first non-profit
dermal substitute derived from glycerol preserved, human
allogeneic skin [4–6]. Glycerol preserved allogeneic skin (GPA)hent University Hospital, B-9000 Gent, Belgium. Tel.: +32 93 32 32 26;
 (S. ).
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thickness burns and as a means of wound bed preparation on
excised burns. Allograft coverage prevents dehydration and
infection of the wound and stimulates granulation formation
to prepare the wound for closure with autologous skin [5,6].
Allografts contain donor cells, which are ultimately rejected
and can therefore only be used as temporary wound coverage.
Glyaderm1, which is decellularized by treatment with sodium
hydroxide (NaOH), can be used to replace lost dermis in full
thickness wounds serving as a dermal substitute. Glyaderm1
consists of a collagen and elastin fiber network with native
collagen and can ensure a bilayered skin restoration in
combination with a thin autologous split skin graft. It is
intended to be cost-effective and easy to use for widespread
application in full thickness wounds such as full thickness
burns. Glyaderm1 is placed in a wound bed prepared with
allografts, after which, a thin autologous split thickness skin
graft (STSG) will close the wound following Glyaderm1
ingrowth. Animal studies showed favorable results in terms
of tissue integration and wound contraction and scar quality [6].
We first initiated a phase I pilot study to elucidate the most
practical protocol for Glyaderm1 application and to further
investigate the scope of use of the dermal matrix in the clinical
setting.
The second study was a phase III randomized, controlled,
paired, intra-individual comparison of full thickness skin
defects engrafted with Glyaderm1 and STSG versus STSG
alone.
2. Materials and methods
2.1. Enrollment
Between September 2005 and October 2010 27 patients were
recruited for the pilot study and 28 patients met the criteria for
inclusion in the randomized controlled, paired, intraindivi-
dual trial.
Study protocols were approved by the Ghent University
Hospital Ethics Committee.
Glyaderm1was produced and provided by Euro Skin Bank,
Beverwijk, The Netherlands. The preparation steps of Glya-
derm1 have been described previously [6].
2.2. Phase I pilot study
The pilot study was initially performed to assess the scope of
clinical applications of Glyaderm1 as a dermal substitute and
to optimize usage protocol. Patients with full thickness burns,
but also other full thickness skin defects were considered
eligible for this study.
All burn wounds that were not clearly full thickness on
clinical assessment were treated during the first 48 h with an
enzyme alginogel (Flaminal1 Forte – Flen Pharma) [7] and
covered with a paraffin gauze dressing (Jelonet1 – Smith &
Nephew). Flaminal1 Forte combined with Jelonet1 ensured
maintenance of a moist wound environment [7] for the first
48 h prior to assessment by laser Doppler imaging (LDI). This is
the standard treatment for all burns admitted to the Ghent
Burn Center.In our burn center we use the moorLDI2-BI imager (Moor
Instruments Ltd., Axminster, UK) to objectively determine the
healing potential of the burn [8]. LDI is now becoming a
standard of care for early diagnosis of healing potential, which
is a main determinant of subsequent treatment policy. In
clinical trials LDI ensures exact comparison between two
burns without depth difference bias.
In this study, besides clinical observation, LDI was also
intended to monitor the rate of vascularization into the dermal
substitute and thereby to delineate the optimal time between
the application of Glyaderm1 and the final coverage with an
autologous STSG. Ingrowth of blood vessels into Glyaderm1,
resulting in increased blood flow through the dermal substi-
tute, was assessed by means of LDI at day 1, 3, 5 after the
application of Glyaderm1 to the wound. An increase in flux
values over the measurement period was interpreted as
increased blood vessel ingrowth. Biopsies were harvested
before autografting to support this hypothesis. In order to
visualize blood vessel ingrowth into Glyaderm1 the sections
taken from the biopsies were colored with antibodies against
alfa-smooth muscle actin (ASMA) in order to demonstrate the
presence of myofibroblasts and pericytes, which are support-
ing cells for blood vessels.
Efficacy of the protective open pore structure polyamide
dressing (Surfasoft1 – MediProf) and finally the coverage with a
10% povidone iodine (PVP-I) gel (iso-Betadine1 Gel – Meda-
Pharma Belgium) in combination with Jelonet1 was tested.
Outcome measures were percentage of Glyaderm1 take
and percentage of STSG take.
Patients were invited for a long-term follow-up after
complete scar maturation. The long-term scar assessment
included objective measurement of elasticity with the
DermaLab1 (Cortex Technology, Denmark) and measure-
ment of scar erythema and pigmentation with the DermaS-
pectrometer1 (Cortex Technology, Denmark), as well
subjective scar evaluation by means of the adapted Vancouver
Scar Scale (aVSS) and the Patient and Observer Scar Assess-
ment Scale (POSAS). The aVSS, besides scar color, pigmenta-
tion, pliability and scar height also takes into account scar
itching and the presence of defects.
In 4 patients biopsies were taken at 1 month and sent for
histological analysis. Biopsies were fixed in 4% formalin and
were further processed into paraffin. Sections were prepared
and stained with Haematoxilin–Eosin and Elastica von
Giesson to study the presence of Glyaderm1.
3. Phase III study
3.1. Study design
This was a randomized, controlled, paired, intra-individual
comparison of full thickness skin defects engrafted with
Glyaderm1 and STSG (experimental treatment) versus STSG
alone (conventional treatment).
3.2. Study objective
Primary outcome measure was comparison of autograft
survival at one week between full thickness defects treated
with Glyaderm1 plus STSG versus STSG alone.
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cosmetic outcome of skin restoration of full thickness defects
treated with Glyaderm1 plus STSG versus STSG alone 1, 3, 6
and 12 months post wound closure.
3.3. Patient selection
Patients up to 80 years of age with full thickness burns or full
thickness lower arm defects after free flap harvesting were
considered eligible.
Burn wounds had to be either clearly full thickness burns as
clinically assessed by two plastic surgeons, or flux values
measured by LDI had to be below 200, corresponding with a
healing time clearly longer than 21 days.
Eligible patients with the possibility to follow the complete
treatment schedule were consented for the trial.
Patients with one or more serious medical conditions that,
in the opinion of the investigator, made the patient an
inappropriate candidate for the study, or any condition that
seriously compromised the patient’s ability to complete this
study, were excluded. Patients with TBSA of over 40% and
patients who had participated in another study utilizing an
investigational drug within 30 days prior to study inclusion
were also excluded.
3.4. Randomization
The experimental and conventional treatments were confined
to anatomically related areas to allow a paired, intra-
individual comparison. Preferably a right/left comparison
was made; if not feasible, a superior/inferior or medial/lateral
comparison within a wound surface area was performed.
To exclude any bias due to selection of the surgeon or the
researcher, investigators received pre-sealed envelopes con-
taining individual patient’s treatment assignments according
to a predetermined scheme randomizing the experimental
treatment.
Randomization was performed in the operation theater
after the plastic surgeons had removed the allografts used for
wound bed preparation and assessed the wound to be ready
for STSG application. Usually this would be at the second
operation, unless further wound bed preparation with
allografts was necessary at that stage.
3.5. Surgical regimen (Table 1)
The first operation consisted of either full thickness removal of
the burn scar performed as soon as possible after burn depth
diagnosis, or the harvesting of the free radial foream flap
resulting in an almost circumferential (16 cm  13 cm) defect
(Table 1).Table 1 – Phase III randomized trial patient treatment scheme
Glyaderm1 + STSG
(experimental treatment)
Wound bed preparation 1st operation: Allograft 
Dermal substitute 2nd operation: Glyaderm1
Autografting 3rd operation: STSG In both cases this was followed by application of glycerol
preserved allografts meshed 1:2 for wound bed preparation.
The second operation was performed 5–10 days after the
first operation and the surgery to be performed depended
upon the quality of wound bed preparation with the allografts.
If wound bed preparation was not satisfactory, allograft
application would be repeated.
If wound bed preparation was satisfactory the experimen-
tal (Glyaderm1 + STSG) and conventional (STSG) treatments
were confined to anatomically related areas to allow a paired,
intra-individual comparison according to the randomization
scheme.
After removal of the allografts and scrubbing with a PVP-I
10% solution (iso-Betadine1 Dermicum – MedaPharma
Belgium) and saline, and hemostasis with adrenaline soaked
gauzes, the wounds were treated with sutured or stapled
application of Glyaderm1, perforated 1:1, on the treatment
side and renewed application of allograft on the conventional
treatment side. Both wounds were covered with Surfasoft1.
Final operation, also performed 5–7 days after treatment
confinement, as guided by clinical assessment and supported
by LDI, consisted of the removal of the allografts at the
conventional side and gentle scrubbing of the Glyaderm1
dermal matrix and the application of a STSG (0.010 in) on top of
both study treatment areas. Mesh ratio was always similar for
the experimental side as well as for the conventional
treatment side. Autografts were covered with Surfasoft1.
3.6. Wound treatment regimen
All burn wounds that were not clearly full thickness on initial
clinical assessment were treated once daily during the first
48 h with iso-Betadine1 Dermicum for decontamination
followed by application of Flaminal1 Forte covered with a
Jelonet1 dressing and a dry sterile gauze dressing. Clearly full
thickness burns were treated with cerium nitrate–silver
sulphadiazine (Flammacerium1 – Sinclair Pharmaceuticals
Ltd.) until the first operation.
Allografts were covered daily with iso-Betadine1 gel and
Jelonet1 until the next operation. The same applies to
Glyaderm1.
Autografts were dressed with Jelonet1, iso-Betadine1 gel
and a covering dry sterile gauze dressing until day one post
application after which the wounds were dressed daily with,
iso-Betadine1 Dermicum soaked gauzes, Jelonet1 and dry
sterile gauze until removal of the Surfasoft1 layer at day 6–7.
Donor sites were dressed with Hydrofiber1 silver dressings.
3.7. Study assessments
All data were recorded in a purpose designed database..
STSG alone
(conventional treatment)
1st operation: Allograft Wound bed preparation
2nd operation: Allograft
3rd operation: STSG Autografting
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Patient demographics were recorded at study inclusion.
Patient gender, age, burn cause, total body surface area (TBSA)
that was burned in %, burn body location, TBSA represented by
the target wounds in % were noted.
3.7.2. Wound evolution
Clinical wound assessments were conducted twice weekly
from inclusion to full wound closure. Wounds were photo-
graphed, if possible, the day of, or after admission and also the
day of LDI and thereafter twice weekly and at every surgical
procedure.
Wound swabs were harvested for semi-quantitative and
qualitative microbiological investigation on admission, on the
day of LDI and then repeatedly on a weekly basis from the
region of interest as well as other burn areas according to a
standard microbiology swab procurement regimen which
exists as an integral part of the Ghent Burn Center wound care
policy.
3.7.3. Take rates
Glyaderm1 was evaluated with LDI at postoperative day 1, 3
and 5 for vascular ingrowth. Glyaderm1 take rates were scored
at day 6–7 post Glyaderm1 application, during the autograft
procedure. STSG take rates were scored at day 6–7 post
autograft application and after Surfasoft1 removal.
3.8. Treatment after wound closure
3.8.1. Pressure garments and silicones
Scar treatment was the same for both groups and consisted of
custom made pressure garments and/or silicone garments.Table 2 – Patients pilot study.
Pat no. Gender Age (years) 
1 Male 33 Burn
2 Female 32 Burn
3 Male 47 Burn
4 Female 74 Burn
5 Female 29 Burn
6 Male 3 Gian
7 Male 1 Burn
8 Female 56 Burn
9 Male 20 Burn
10 Female 6 Burn
11 Male 34 Degl
12 Male 2 Gian
13 Female 58 Skin
14 Female 8 Burn
15 Male 2 Burn
16 Female 47 Burn
17 Male 24 Radi
18 Male 25 Radi
19 Male 40 Radi
20 Female 54 Burn
21 Female 51 Fasc
22 Female 60 Burn
23 Female 51 Burn
24 Male 28 Burn
25 Male 27 Radi
26 Male 10 Burn
27 Male 50 RadiThere was an individual and especially adapted schedule
worked out for every patient, regarding the silicone pressure
garments.
3.8.2. Hydration of the scar
Hydration of the dry skin is necessary at least three times a
day. All patients were using the same product Alhydran1
(BAP-Medical) [9] during the complete follow-up period of 1
year.
3.9. Follow-up assessments
At regular follow-up of 1, 3, 6 and 12 months objective and
subjective scar assessment was performed.
Objective evaluation of elasticity was performed using the
DermaLab1. For color and pigmentation assessment of the
scar, the DermaSpectrometer1 was used.
For subjective measurements of quality of scar formation
as for example the degree of hypertrophic scarring the aVSS as
well as a subjective 5 Point Contour Scale, grading from severe
contour deformity to normal anatomical contour, were used.
3.10. Statistical analysis
Statistical analysis was performed with SPSS 21.0 for
Windows. Besides descriptive statistics, non-parametric sta-
tistical analysis of the groups was performed using Mann–
Whitney U-test.
Statistical significance was declared if p  0.05.Etiology Localization LDI
 wound Face right No
 wound Arm right No
 wound Hand right Yes
 wound Breast right Yes
 wound Thorax/abdomen No
t naevus Lower leg right Yes
 wound Hand left & right No
 wound Neck Yes
 wound Hand right Yes
 wound Arm right Yes
ovement Foot right Yes
t naevus Upper leg right Yes
 tear Lower leg left Yes
 wound Arm right Yes
 wound Arm left Yes
 wound Neck Yes
al forearm flap Forearm left Yes
al forearm flap Forearm left Yes
al forearm flap Forearm left Yes
 wound Face Yes
iotomy Lower leg left No
 wound Upper leg right Yes
 wound Upper arm left Yes
 wound Upper arm right Yes
al forearm flap Forearm left, thigh left Yes
 wound Thorax/abdomen Yes
al forearm flap Forearm left Yes
Table 3 – Phase I pilot study patient enrollment.
27 pt s (pat ients) 
Burn wound:  n = 17 pts 
Oth er:  n = 10 pt s 
Included: 24  pt s 
Burn wound:  n = 17 pts 
Oth er:  n = 7 pts 
Long term follow -up: n = 16 pts 
b u r n s 4 1 ( 2 0 1 5 ) 1 3 2 – 1 4 41364. Results
4.1. Phase I pilot study
4.1.1. Baseline group characteristics
Twenty seven patients, with a mean age of 32.30 years
(21.02), were recruited for the pilot study (Tables 2 and 3). In
one patient who received Glyaderm1 after excision of a giant
naevus, Glyaderm1 was lost due to infection with pseudomo-
nas aerigunosa. After removal of the Glyaderm1, control of
infection and renewed wound bed preparation, the wound
was re-grafted with Glyaderm1 and STSG with full take. In 3
patients with a full thickness skin defect after radial forearm
flap harvest and immediate application of Glyaderm1, there
was no ingrowth of Glyaderm1. The protocol was changed to
application of allografts to allow adequate wound bed
preparation prior to application of Glyaderm1. After this
change the Glyaderm1 ingrowth in patients with radial
forearm flap defects was satisfactory.
4.1.2. Take rates
Mean Glyaderm1 take rate in the patients with Glyaderm1
ingrowth was 91.55% (14.59) and 75% of those patients had aFig. 1 – Histological analysis (ASMA staining) visualizing
blood vessel ingrowth into GlyadermW 1 week after its
application to the wound bed.Glyaderm1 take rate of 95% or higher. Mean STSG take rate
after Glyaderm1 ingrowth was 96.67% (4.75).
LDI demonstrated enhanced vascularization from day 1 to
day 7, corresponding with both ASMA stained sections from
biopsies (Fig. 1), harvested before autografting, and clinical
observation of the dermal substitute starting at day of
Glyaderm1 application until day of autografting. The color
coded map on the computer, created by the measured flux
values, allowed us to delineate the optimal engraftment
interval. The optimal time before application of a STSG on top
of the Glyaderm1 was 6 days with a 1 day standard deviation
as shown in Fig. 2.
All patients responded well to a dressing regimen of
Surfasoft1) for protection of the Glyaderm1 combined with
iso-Betadine1 Gel and Jelonet1 in terms of bacterial control
and prevention from dehydration and desiccation of the
Glyaderm1.
Histological analysis with Elastica von Giesson staining, of
the biopsies taken at 1 month post wound healing, confirmed
the presence of a native and vascularized collagen–elastin
matrix embedded between the epidermis and the subcutane-
ous layer, thus recreating a neodermis as shown in Fig. 3.
4.1.3. Long-term follow-up (Table 4)
In total 16 patients participated in the long-term follow-up
after Glyaderm1 scar maturation (Table 4).
Elasticity measurements with the DermaLab1 resulted in
an average young modulus of 8.51 (4.12) for Glya-
derm1 + STSG and 6.77 (3.78) for normal skin. Statistics
using the Mann–Whitney test demonstrated that, within this
group of 16 patients, elasticity of Glyaderm1 + STSG is not
significantly different from the elasticity of normal skin
( p = 0.319).
DermaSpectrometer1 measurements for erythema were
on average 15.21 (5.31) for Glyaderm1 + STSG and 11.66
(3.14) for normal skin. Erythema measured in Glyaderm1 did
not differ significantly from erythema measured in normal
skin (Mann–Whitney test, p = 0.052).
DermaSpectrometer1 measurements for pigmentation
were on average 31.69 (4.67) for Glyaderm1 + STSG and
33.34 (2.90) for normal skin. Pigmentation measured in
Glyaderm1 did not differ significantly from pigmentation
measured in normal skin (Mann–Whitney test, p = 0.120).
POSAS score for general impression of the Glya-
derm1 + STSG was on average 4.25 (1.81) for the investiga-
tors and 3.77 (2.62) for the patients. The POSAS score varies
between 1 and 10 with 1 meaning the scar equals normal skin
and 10 equaling the worst imaginable scar. From a statistical
point of view there was no difference between the scores of
investigators and patients (Mann–Whitney test, p = 0.288).
Adapted Vancouver Scar Scale equalled 3.81 (2.26) on
average, where the values for aVSS can vary between 0 (best
score) and 18 (worst score).
In the absence of statistically significant differences
between Glyaderm1 + STSG and normal skin we therefore
concluded that long-term results of the phase I pilot study
proved Glyaderm1 to be a suitable dermal matrix for full
thickness burns and large soft tissue defects as also illustrated
in Figs. 4–6.
Fig. 2 – Laser Doppler imaging of GlyadermW vascularization.
Fig. 3 – Histological analysis (Elastica von Giesson staining)
1 month post wound healing of pilot study area treated
with GlyadermW.
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4.2.1. Baseline group characteristics
Thirty patients (34 sites) were eligible for inclusion in the study
(Table 5). Two patients (two sites) were excluded prior to the
Glyaderm1 procedure. Twenty-eight patients with a mean age
of 33.07 years (10.35) and representing 32 sites met the
inclusion criteria and were included in the study.
There were 9 patients with full thickness burns (13 sites)
and 19 patients (19 sites) with full thickness defects after
radial forearm flap harvest (Figs. 7 and 8). Two sites (one in
each group) were lost during the procedure due to no
Glyaderm1 ingrowth. Subsequent regrafting with Glyaderm1
and skin graft showed good take but these were excluded
from the study.
4.2.2. Primary outcome measures (Table 6)
Mean wound surface area of the wounds treated with
Glyaderm1 + STSG was 186.84 cm2 (165.20) and mean wound
surface area of the wounds treated with STSG alone was
184.33 cm2 (175.87). Both procedures, as compared in this
study, were comparable for treated wound surface area
(Mann–Whitney test, p = 0.536) (Table 6).
Mean Glyaderm1 take rate in the included patients was
88.17% (18.34). Mean STSG take rate after Glyaderm1
ingrowth was 92.47% (23.19). STSG take rate in the wounds
not treated with Glyaderm1was 97.68% (4.99). The take rates
Table 4 – Phase I pilot study overview of statistical results (long-term follow up).
Variable Statistical analysis p-Value Advantage
Elasticity (long term follow up)
Glyaderm1 + STSG versus normal skin
Mann–Whitney test 0.319 Glyaderm1 + STSG compares to normal skin
Erythema (long term follow up)
Glyaderm1 + STSG versus normal skin
Mann–Whitney test 0.052 Glyaderm1 + STSG compares to normal skin
Pigmentation (long-term follow up)
Glyaderm1 + STSG versus normal skin
Mann–Whitney test 0.120 Glyaderm1 + STSG compares to normal skin
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different from the STSG take rates in the group with a STSG
alone (Mann–Whitney test, p = 0.588). Non-parametric statis-
tical analysis in the subgroups based on wound etiology also
resulted in comparable STSG take rates for burn wounds
(Mann–Whitney test, p = 0.671) and for full thickness skin
defects after radial forearm flap harvesting (Mann–Whitney
test, p = 0.845).
4.2.3. Secondary outcome measures (Table 6)
4.2.3.1. Elasticity. On average, elasticity (Young modulus)
measured 1 month after wound healing was 8.81 (1.50) for
Glyaderm1 + STSG and 10.31 (0.84) for STSG alone. 12
months after wound healing the Young modulus values
averaged 8.89 (1.10) for Glyaderm1 + STSG and 9.29 (0.99)
for STSG alone. Comparing the DermaLab1 measurements of
‘‘Glyaderm1 + STSG’’ versus ‘‘STSG alone’’ statistics indicate
that: Glyaderm1 + STSG’’ has significantly more elasticity
when compared to ‘‘STSG alone’’ 1 month (Mann–Whitney
test, p = 0.001) and 12 months (Mann–Whitney test, p = 0.003)
after wound closure.
One year after wound closure we measured a mean Young
modulus of 6.71 (0.16) on normal skin which was significantly
more elastic than both Glyaderm1 + STSG (Mann–Whitney test,
p < 0.0001) and STSG alone (Mann–Whitney test, p < 0.0001).
4.2.3.2. Color and pigmentation. Measurements with the Der-
maSpectrometer1 for erythema and pigmentation performed
at 1 month and 12 months after wound closure did not
result in statistically significant differences between ‘‘Glya-
derm1 + STSG’’ and ‘‘STSG alone’’.
4.2.3.3. Scar scales. When looking at the aVSS at 12 months,
with a mean score of 3.27 (2.76) for Glyaderm1 + STSG and
4.73 (2.01) for STSG alone, scoring is on average better for
Glyaderm1 although there is no significant difference from aFig. 4 – Full thickness burstatistical point of view (Mann–Whitney test, p = 0.682).aVSS
scores for Glyaderm1 noted in this study were comparable to
aVSS scores for Glyaderm1 observed in the pilot study.
Independent blinded expert observers were asked to designate
which of the intra-individual compared areas, according to
their personal opinion, demonstrated best scar quality.
According to these blinded expert observers best scar quality
is mainly observed in Glyaderm1 treated wounds (82%) as
shown in Fig. 9.
5. Discussion
Excessive scar formation accounts for major morbidity and a
continuing challenge in burn treatment [10]. Elasticity,
flexibility, and strength of the normal dermis is compromised
in scar tissue which can limit movement, causes pain, and is
cosmetically undesirable [11,12]. The pivotal role of an
adequate amount of dermis in surgical skin resurfacing is
being increasingly understood and embraced [4]. The empha-
sis in surgical burn care has shifted from pure survival to
quality of life after survival with increased interest in
improvement of functional and esthetic scar outcomes.
Dermal substitution is becoming more and more a standard
procedure in surgical burn reconstruction. Dermal substitutes
are also being used for bi-layered skin resurfacing after trauma
or (oncological) resections and in the field of breast recon-
struction and hernia repair [13,14].
Elastin is historically underrepresented in commercial
dermal substitutes, yet it serves a fundamental role in skin
structure and function. The dermal elastic network deter-
mines skin resilience, texture, and quality but is poorly
regenerated following burn [15]. In addition to its structural
and mechanical functions, elastin has inherent cell signaling
properties that promote a diverse range of cellular responses
including chemotaxis, cell attachment, proliferation, andn in a 1 year old boy.
Fig. 5 – Full thickness burn in a 54 year old woman.
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elastic fiber system is important for the development of
functional dermal substitutes [15].
Collagen has been used in most dermal substitutes as it
makes up the largest portion of the dermis, is biologically
tolerated, and has well-defined structural, physical, and
biological properties.Fig. 6 – Giant Naevus inOne of the earliest and still most widely used commercial
collagen-based dermal substitutes is Integra1 [1–3]. It consists
of a porous dermal layer made from bovine collagen and
chondroitin-6-sulfate and a temporary silicone layer that acts
as a barrier between the body and the environment. The
silicone layer is replaced with a thin skin autograft following
the substitute vascularization. a 4 year old boy.
Table 5 – Phase III randomized trial patient enrollment.
34 sites / 30 pts (patient s) 
BW site s (burn wound): n  = 14 (10 pts) 
RFF site s (radial forearm flaps):  n = 20 (20 pt s) 
Included: 32 site s / 28  pts  
BW:  n = 13 (9 pts) 
RFF:  n = 19 (19 pts) 
Excluded (prior to glyaderm procedure) 
BW:  n = 1 (1 patient) 
RFF:  n = 1 (1 patient)  
Burn patients 
Sites complet ed  glyader m procedure: 
n = 12 (8 pt s) 
 
Lost through procedure: n = 1 (no 
glyader m take)  
Radial forearm  flap pat ien ts 
Sites complet ed  glyader m procedure: 
n = 18 (18  pts) 
 
Lost through procedure: n = 1 (no 
glyader m take)  
Follow-up: n = 12 (8 pts) Follow-up: n = 18 (18 pt s) 
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degraded and replaced by native collagen deposited by host
fibroblasts.
Collagen-based scaffolds currently dominate the dermal
substitute field but are restricted by their lack of elasticity and
impaired by scaffold contraction during repair [16,17].
Scaffold elasticity and regeneration of the elastic fiber
system are now recognized as integral to the development of
functional dermal substitutes [18–23].Fig. 7 – Full thickness burn in a 3 year old boy (left fThe presence of elastin in collagen-based scaffolds has
been shown to decrease scaffold stiffness [24] and modulate
collagen contraction [25,26]. There is evidence suggesting that
elastin can suppress the differentiation of proliferating
fibroblasts into contractile myofibroblasts [27], thereby reduc-
ing wound contraction and modulating scar tissue formation.
Elastin does not adequately regenerate during severe wound
healingandits distributionisdisruptedincutaneousscars [15]. It
takes 4–5 years for elastin expression to rise following culturedoot = GlyadermW + STSG/right foot = STSG alone).
Fig. 8 – Radial forearm flap (GlyadermW + STSG side).
b u r n s 4 1 ( 2 0 1 5 ) 1 3 2 – 1 4 4 141epithelial autograft (CEA) treatment of burn wounds. Elastin is
functionally and spatially disorganized in scar tissue [28,29].
Expression of both elastin and fibrillin-1 are reduced in scar
tissue with a particularly prominent reduction in hypertrophic
scars [15]. Newly synthesized, elastic fibers in scar tissue
always appear thin, fragmented, and less mature than elastic
fibers in normal skin [15,29,30]. Even in scars older than 10
years, elastic fibers never reach the size and maturity of
healthy skin [30], which attributes to the fact that hypertro-
phic scars are usually hard and inelastic [29].Table 6 – Phase III randomized trial overview of statistical res
Variable Statistica
Mean wound surface area treated
Glyaderm1 + STSG versus STSG alone
Mann–Whi
Mean STSG take rate (%)
Glyaderm1 + STSG versus STSG alone
Mann–Whi
Elasticity (1 month after wound closure)
Glyaderm1 + STSG versus STSG alone
Mann–Whi
Elasticity (1 year after wound closure)
Glyaderm1 + STSG versus STSG alone
Mann–Whi
Elasticity (1 year after wound closure)
Glyaderm1 + STSG versus normal skin
Mann–Whi
Elasticity (1 year after wound closure)
STSG alone versus normal skin
Mann–Whi
Erythema (1 month after wound closure)
Glyaderm1 + STSG versus normal skin
Mann–Whi
Erythema (1 year after wound closure)
Glyaderm1 + STSG versus STSG alone
Mann–Whi
Pigmentation (1 month after wound closure)
Glyaderm1 + STSG versus STSG alone
Mann–Whi
Pigmentation (1 year after wound closure)
Glyaderm1 + STSG versus STSG alone
Mann–Whi
Adapted Vancouver scar scale (1 year after wound closure)
Glyaderm1 + STSG versus STSG alone
Mann–Whi
The bold p-values indicate statistical significance.The disruption of the elastic fiber system in healing
wounds and scar tissue is well documented, but the mecha-
nism behind this phenomenon is not clear. It is possible that
elastin upregulation in healing wounds is not sufficient to
regenerate robust elastin fibers.
Elastin-containing dermal substitutes may improve the
elasticity and functionality of severe scars by replacing the
missing elastic network or by signaling the upregulation of
elastic tissue biosynthesis. Consistent with this signaling role,
dermal fibroblasts display increased elastin expression whenults.
l analysis p-Value Advantage
tney test 0.536 Glyaderm1 + STSG compares to STSG alone
tney test 0.588 Glyaderm1 + STSG compares to STSG alone
tney test 0.001 Glyaderm1 + STSG
tney test 0.003 Glyaderm1 + STSG
tney test <0.0001 Normal skin
tney test <0.0001 Normal skin
tney test 0.072 Glyaderm1 + STSG compares to STSG alone
tney test 0.786 Glyaderm1 + STSG compares to STSG alone
tney test 0.581 Glyaderm1 + STSG compares to STSG alone
tney test 0.828 Glyaderm1 + STSG compares to STSG alone
tney test 0.682 Glyaderm1 + STSG compares to STSG alone
Fig. 9 – Best scar quality as subjectively attributed by
independent blinded expert observers (phase III
randomized trial).
b u r n s 4 1 ( 2 0 1 5 ) 1 3 2 – 1 4 4142they are stimulated with proteolytic digests of bovine elastin
introduced into the skin of nude mice or into human skin
explants [31].
Collagen–elastin composite scaffolds induce elastin depo-
sition when implanted subcutaneously in rats, compared with
collagen-only scaffolds that do not promote elastin synthesis
[32,33].
The clinically best known human decellularized, collagen–
elastin dermis is sodium chloride–sodium dodecyl sulfate-
treated cadaver skin marketed as AlloDerm1 [34]. AlloDerm1
has been applied to human burns in a range of different
procedures [34–37]. AlloDerm1-grafted sites often show good
cosmetic and functional results, with limited contractures
observed on relatively small burn areas (<20% TBSA) [35]. Case
studies also report increased skin elasticity and improved
cosmetic appearance when AlloDerm1 is grafted with split
thickness autografts, compared with split-thickness autografts
alone [34,35]. When applied to burned joints, AlloDerm1 can
minimize wound contraction and allow joint movement [37].
Becauseofitshighcostandlimitedquantity,AlloDerm1 ismostly
used in reconstructive surgery to release skin contractures and
hypertrophic scars [37]. The cost of Alloderm1 as mentioned by
Butterfield in a 2013 review article was 21.7 Euro/cm2 [38].
Another dermal matrix consisting of native bovine collagen
(type I, III and V) fibers was coated with 3% (w/w) a-elastin
derived from bovine ligamentum nuchae, marketed as
MatriDerm1. MatriDerm1 in combination with a split-thick-
ness mesh graft showed improved skin pliability and elasticity
compared with split-thickness mesh grafts alone in scar
reconstruction wounds. However, these benefits were not
seen in burn wounds after 3 months [39]. In a scar follow-up
study, no difference in scar elasticity was observed between
MatriDerm1-grafted and control scars in the burn wounds at
12 years post grafting. However, there was a perceived
improvement for MatriDerm1-grafted wounds compared with
control wounds in subjective scar assessment conducted by
patients and clinicians [38]. MatriDerm1 has proved particu-
larly useful in the treatment of hand burns, which are reported
in 60–90% of burn cases [40,41]. A long-term follow-up of
upper-extremity wounds treated with this scaffold in combi-
nation with a sheet autograft reveals good skin pliability, scar
height, and ultimately, hand function [41]. Radu et al. found
that MatriDerm1 when used in combination with a split-
thickness autograft improved the range of motion and thequality of scars compared with split-thickness grafts alone
[42]. The beneficial effects of MatriDerm1, including the
reduction of wound contraction and stimulation of dermal
regeneration, are believed to be conveyed in the early healing
stages (within the first 2 weeks) through the inhibition of
dermal fibroblast differentiation into contractile myofibro-
blasts [25].
MatriDerm1 is a first step toward incorporation of soluble
elastin derivatives in dermal substitute scaffolds. MatriDerm1,
however, consists of a collagen scaffold coated with elastin, and
its benefits are therefore not derived from the presence of an
elastin fiber network or elasticity of the scaffold. The porous
nature of the matrix may support a more rapid vascularization
of the matrix, however the absence of elastin fibers and thus a
network of elastin may also diminish its long-term beneficial
effect in terms of elasticity. Further, the scaffold is composed of
animal derived proteins, which carry risks of immune rejection
and pathogen transfer as well as suffer from potential
heterogeneity because of their batch-to-batch inconsistencies.
The cost of MatriDerm1 as mentioned by Lamy et al. in a 2013
article is on average 5.30 Euro/cm2 [43].
Increasing understanding of the importance of elastin in
tissue-engineered scaffolds has resulted in research into the
elastin- and tropoelastin-based scaffolds. These scaffolds are
currently undergoing in vitro and early in vivo testing [44]. In
the clinical setting often logistic, financial and temporal issues
continue to challenge the burn surgeon to use dermal
substitutes on a more larger scale.
We set out to develop a dermal substitute from glycerol
preserved allografts more than a decade ago, which was
intended to have the following key advantages: native
collagen and elastin matrix, easy storage and handling,
inactivation of virus and micro-organisms [45,46] and most
importantly, a non-profit product that could be available to a
larger number of patients. The extreme high cost of dermal
substitutes today impedes their widespread application and
benefit for those who need it the most. As clinicians in the field
our chief aim was to develop a practical and affordable dermal
substitute for burn, cancer and trauma victims.
The most favorable prototype Glyaderm1 was tested in
animal studies, which showed favorable results in a three
stage procedure, allograft, Glyaderm1, autograft (manuscript
in preparation). These promising results prompted the current
pilot study and randomized comparison.
There have been many reports attesting the benefits of
various dermal substitutes. However, to our knowledge there
has been no conclusive randomized trial which demonstrates
a superior outcome of skin resurfacing with a dermal
substitute and split skin graft over skin resurfacing with a
skin graft alone. Most burn experts do not question the value
of dermal substitution in surgical burn care and long-term
results of patients attest the added value.
Objective scar assessment and longer follow-up is eluci-
dating this advantage, which is already clinically apparent.
Our pilot study shows consistent, stable long-term results
after 6 years with pliable skin after bi-layered skin restoration
with Glyaderm1.
Objective scar assessment showed a significantly improved
elasticity of the skin in patients treated with Glyaderm1 and
skin graft compared to skin graft alone ( p = 0.003).
b u r n s 4 1 ( 2 0 1 5 ) 1 3 2 – 1 4 4 143Glyaderm1 is the first cost-effective, non-profit, dermal
substitute that can be compared with currently available
dermal equivalents.
To our knowledge we are the first to show that laser
Doppler imaging allows monitoring of vascular ingrowth in
dermal substitutes such as Glyaderm1. Although most burn
experts advocate the use of dermal substitutes, the challenge
remains to objectively show the perceived benefit over split
skin grafting alone. The evolving evaluation with objective
scar assessment tools within these studies may help to further
demonstrate this benefit in the near future.
A disadvantage in our initial studies with Glyaderm1
was the necessity for three procedures to full wound
closure. Direct application of Glyaderm1 onto the wound
bed without allograft wound bed preparation did not seem
to be a viable option in either the animal studies nor the
phase I pilot study as demonstrated by the 3 patients with a
full thickness skin defect after radial forearm flap harvest
where, following immediate application of Glyaderm1, we
expected no problems in view of the healthy wound bed,
but in the end there was no ingrowth of the dermal
substitute. The animal studies had also pointed out that
simultaneous application of Glyaderm1 and autograft was
not feasable. In Glyaderm1 processing a relative dense
elastin-collagen network is preserved. Budding capillaries
need to penetrate this network before they can nourish the
overlying autograft. In addition, the earlier Glyaderm1
prototypes were relatively too thick and suffered from
batch to batch inconsistencies inherent to variation in
selection. Continuous research, monitoring of selection and
development improved this process of graft selection and
standardization.
A purpose designed laser tool is now used to ensure
selection of dermis of uniform thickness. The laser accurately
scans the distance between the optic and the table and the
optic and the Glyaderm1 subsequently placed upon the table,
allowing the difference in height to be the thickness.
The optimal 0.2–0.4 mm thickness glycerol preserved
dermis is now selected for processing into Glyaderm1.
Glyaderm1 is currently applied with simultaneous skin
grafting after wound bed preparation with allografts for 5 days.
This improvement has a distinct favorable impact on morbidity
and cost [47]. We have now modified the study protocol of a
recent ongoing multicentre Glyaderm1 study to allow for
recruitment of patients with this shorter surgical procedure.
Glyaderm1 is produced by the Euro Skin Bank, Beverwijk,
The Netherlands, a non-profit tissue bank that also monitors
Glyaderm1 commercial distribution for burn care and
reconstructive procedures.
Euro Tissue Bank ensures the quality and non-profit
distribution of the product backed by a clinical specialist
advisory group to facilitate and promote clinical use.
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